Remdesivir News and Research

RSS

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New study describes SARS-CoV-2 ExoN enzyme that promotes antiviral resistance

A new study describes the structure of a crucial enzyme present in SARS-CoV-2.

8 Aug 2021

Could a plant metabolite in liverworts be a potent antiviral against SARS-CoV-2 and other RNA viruses?

A new study from the National Centre for Biotechnology and Medicinal Chemistry Institute suggests Mother Nature delivered — in the form of liverworts. They found that the bryophyte Marchantia polymorpha, also known as umbrella liverworts, could work as a potential antiviral treatment.

5 Aug 2021

Water-soluble vitamin E compounds directly inhibit SARS-CoV-2 replication and synergize with remdesivir

Researchers in the United States have shown that water-soluble derivatives of vitamin E (α-tocopherol) exhibit potent antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Jul 2021

Could corticosteroids increase mortality in COVID-19 patients without high oxygen supplementation?

A new paper focuses on the role of corticosteroids, in particular, as these were widely used among patients on intensive respiratory support (IRS).

14 Jul 2021

Molecular dynamic analysis of SARS-CoV-2 inhibitors

A new study reports the results of molecular dynamic simulations that were performed in an effort to identify new drugs that could be effective against SARS-CoV-2.

13 Jul 2021

Scientists identify existing drugs that may inhibit SARS-CoV-2 virus

The COVID-19 pandemic has caused more than 600,000 deaths in the United States since the start of 2020 and more than 4 million globally.

13 Jul 2021

Investigation reveals considerable added benefit of remdesivir for moderately ill COVID-19 patients

Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation.

6 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

The use of flavonoids as antiviral agents against SARS-CoV-2

Researchers in Iran have undertaken a comprehensive review of flavonoids and their antiviral potential against SARS-CoV-2.

2 Jul 2021

Stool transplant may be worth exploring as treatment option for COVID-19

It might be worth exploring stool transplant to treat COVID-19 infection, suggest doctors in a letter published online in the journal Gut, after they used the procedure in two patients to prevent the recurrence of another bacterial infection.

2 Jul 2021

Anti-malarial drug shows promise in the battle against COVID-19

In the "war" that the world has been fighting against COVID-19, scientists have been scanning their arsenals of previously used drugs in hopes of finding any that can be used to treat the disease.

1 Jul 2021

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Study suggests vitamin B12 as a SARS-CoV-2 antiviral

Researchers in the UK and Spain have used a novel drug screening approach to identify compounds that could serve as effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

28 Jun 2021

Remdesivir caused dangerously low heart rate in COVID-19 patients

After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.

25 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.